# Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

> **NCT07245771** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ikaria Bioscience Pty Ltd** · enrollment: 104 (estimated)

## Conditions studied

- Obesity &Amp; Overweight

## Interventions

- **DRUG:** RN3161
- **DRUG:** Placebo Control
- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT07245771
- **Lead sponsor:** Ikaria Bioscience Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2027-02-15
- **Final completion:** 2027-08-15
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07245771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07245771, "Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07245771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*